Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Combined With Azacytidine and HAG Regimen for Relapsed/Refractory AML
NCT05029141Phase 2Active, not recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Sep 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Started Sep 2021; status: active, not recruiting.
02
Drugs
tucidinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05029141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05029141.